Marketing-authorisation holder
Otsuka Pharmaceutical Co., Ltd.
38 medicines in 2 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
38 medicines in 2 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 38
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABILIFY2 mg · Tablet | Aripiprazole | Canada | Marketed | 2009 |
| ABILIFY10 mg · Tablet | Aripiprazole | Canada | Marketed | 2009 |
| ABILIFY15 mg · Tablet | Aripiprazole | Canada | Marketed | 2009 |
| ABILIFY30 mg · Tablet | Aripiprazole | Canada | Marketed | 2009 |
| ABILIFY5 mg · Tablet | Aripiprazole | Canada | Marketed | 2009 |
| ABILIFY20 mg · Tablet | Aripiprazole | Canada | Marketed | 2009 |
| ABILIFY ASIMTUFII960 mg / 3.2 ml · Suspension (Extended-Release) | Aripiprazole | Canada | Marketed | 2025 |
| ABILIFY ASIMTUFII720 mg / 2.4 ml · Suspension (Extended-Release) | Aripiprazole | Canada | Marketed | 2025 |
| ABILIFY MAINTENA300 mg / syr · Powder For Suspension (Sustained-Release | Aripiprazole | Canada | Authorised | |
| ABILIFY MAINTENA300 mg / vial · Kit, Powder For Suspension (Sustained-Release | Aripiprazole | Canada | Marketed | 2014 |
| ABILIFY MAINTENA400 mg / syr · Powder For Suspension (Sustained-Release | Aripiprazole | Canada | Authorised | |
| ABILIFY MAINTENA400 mg / vial · Kit, Powder For Suspension (Sustained-Release | Aripiprazole | Canada | Marketed | 2014 |
| DACOGEN50 mg / vial · Powder | Decitabine | Canada | Authorised | |
| JINARC30 mg + 60 mg · Tablet | Tolvaptan | Canada | Marketed | 2015 |
| JINARC30 mg + 15 mg · Tablet | Tolvaptan | Canada | Marketed | 2020 |
| JINARC15 mg + 15 mg · Tablet | Tolvaptan | Canada | Marketed | 2020 |
| JINARC90 mg + 30 mg · Tablet | Tolvaptan | Canada | Marketed | 2015 |
| JINARC45 mg + 15 mg · Tablet | Tolvaptan | Canada | Marketed | 2015 |
| REXULTI3 mg · Tablet | Brexpiprazole | Canada | Marketed | 2017 |
| REXULTI2 mg · Tablet | Brexpiprazole | Canada | Marketed | 2017 |
| REXULTI0.25 mg · Tablet | Brexpiprazole | Canada | Marketed | 2017 |
| REXULTI4 mg · Tablet | Brexpiprazole | Canada | Marketed | 2017 |
| REXULTI1 mg · Tablet | Brexpiprazole | Canada | Marketed | 2017 |
| REXULTI0.5 mg · Tablet | Brexpiprazole | Canada | Marketed | 2017 |
| SAMSCA30 mg · Tablet | Tolvaptan | Canada | Marketed | 2011 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 31 | 27 | 4 | CompaniesAll medicines |
| Saudi Arabia | 7 | 7 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, Singapore, United States
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.